Overview

SCMC Trial on KHE With KMP (V.2020)

Status:
Not yet recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Children's Medical Center

Treatments:

Sirolimus